Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension.

Chin KM, Channick RN, de Lemos JA, Kim NH, Torres F, Rubin LJ.

Chest. 2009 Jan;135(1):130-6. doi: 10.1378/chest.08-1323. Epub 2008 Aug 21.

PMID:
18719056
2.

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.

Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB; PACES Study Group.

Ann Intern Med. 2008 Oct 21;149(8):521-30. Erratum in: Ann Intern Med. 2009 Jan 6;150(1):63. Ann Intern Med. 2009 Sep 15;151(6):435.

PMID:
18936500
4.

Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.

Johnson RF, Loyd JE, Mullican AL, Fink CA, Robbins IM.

J Heart Lung Transplant. 2007 Apr;26(4):363-9. Epub 2007 Mar 2.

PMID:
17403478
5.

Children with pulmonary arterial hypertension and prostanoid therapy: long-term hemodynamics.

Siehr SL, Ivy DD, Miller-Reed K, Ogawa M, Rosenthal DN, Feinstein JA.

J Heart Lung Transplant. 2013 May;32(5):546-52. doi: 10.1016/j.healun.2013.01.1055. Epub 2013 Feb 28.

6.
7.

One-year experience with intravenous treprostinil for pulmonary arterial hypertension.

Benza RL, Tapson VF, Gomberg-Maitland M, Poms A, Barst RJ, McLaughlin VV.

J Heart Lung Transplant. 2013 Sep;32(9):889-96. doi: 10.1016/j.healun.2013.06.008.

PMID:
23953817
8.

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.

Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jöbsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill NS, Langleben D, Schilz RJ, McLaughlin VV, Robbins IM, Groves BM, Shapiro S, Medsger TA Jr.

Ann Intern Med. 2000 Mar 21;132(6):425-34.

PMID:
10733441
9.

Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.

Benza RL, Gomberg-Maitland M, Naeije R, Arneson CP, Lang IM.

J Heart Lung Transplant. 2011 Sep;30(9):982-9. doi: 10.1016/j.healun.2011.03.011. Epub 2011 May 4.

PMID:
21531577
10.

Epoprostenol sodium for treatment of pulmonary arterial hypertension.

Saito Y, Nakamura K, Akagi S, Sarashina T, Ejiri K, Miura A, Ogawa A, Matsubara H, Ito H.

Vasc Health Risk Manag. 2015 May 14;11:265-70. doi: 10.2147/VHRM.S50368. eCollection 2015. Review.

11.

Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.

Sitbon O, McLaughlin VV, Badesch DB, Barst RJ, Black C, Galiè N, Humbert M, Rainisio M, Rubin LJ, Simonneau G.

Thorax. 2005 Dec;60(12):1025-30. Epub 2005 Jul 29.

12.

[Long-term experience with trerpostinil infusion treatment in patients with pulmonary arterial hypertension in the Czech Republic].

Jansa P, Ambroz D, Maresová J, Jelínková L, Polácek P, Palecek T, Aschermann M, Linhart A.

Vnitr Lek. 2007 Apr;53(4):333-7. Czech.

PMID:
17578162
13.

Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study.

Chin KM, Badesch DB, Robbins IM, Tapson VF, Palevsky HI, Kim NH, Kawut SM, Frost A, Benton WW, Lemarie JC, Bodin F, Rubin LJ, McLaughlin V.

Am Heart J. 2014 Feb;167(2):218-225.e1. doi: 10.1016/j.ahj.2013.08.008. Epub 2013 Oct 16.

14.

Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension.

Stiebellehner L, Petkov V, Vonbank K, Funk G, Schenk P, Ziesche R, Block LH.

Chest. 2003 Apr;123(4):1293-5.

PMID:
12684325
15.

Rapid initiation of intravenous epoprostenol infusion is the favored option in patients with advanced pulmonary arterial hypertension.

Kimura M, Tamura Y, Takei M, Yamamoto T, Ono T, Kuwana M, Fukuda K, Satoh T.

PLoS One. 2015 Apr 6;10(4):e0121894. doi: 10.1371/journal.pone.0121894. eCollection 2015.

16.

Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study.

Humbert M, Sanchez O, Fartoukh M, Jagot JL, Le Gall C, Sitbon O, Parent F, Simonneau G.

Eur Respir J. 1999 Jun;13(6):1351-6.

17.

Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?

Steele P, Strange G, Wlodarczyk J, Dalton B, Stewart S, Gabbay E, Keogh A.

BMC Cardiovasc Disord. 2010 Feb 22;10:9. doi: 10.1186/1471-2261-10-9.

18.

Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.

Cabrol S, Souza R, Jais X, Fadel E, Ali RH, Humbert M, Dartevelle P, Simonneau G, Sitbon O.

J Heart Lung Transplant. 2007 Apr;26(4):357-62.

PMID:
17403477
19.

Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.

Melnick L, Barst RJ, Rowan CA, Kerstein D, Rosenzweig EB.

Am J Cardiol. 2010 May 15;105(10):1485-9. doi: 10.1016/j.amjcard.2009.12.075. Epub 2010 Apr 8.

PMID:
20451700
20.

Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry.

Bergot E, Sitbon O, Cottin V, Prévot G, Canuet M, Bourdin A, de Groote P, Rottat L, Gressin V, Jaïs X, Humbert M, Simonneau G.

Int J Cardiol. 2014 Apr 1;172(3):561-7. doi: 10.1016/j.ijcard.2013.12.313. Epub 2014 Jan 22.

PMID:
24529947
Items per page

Supplemental Content

Write to the Help Desk